Prostate Cancer- Epidemiology Forecast to 2030

DelveInsight’s ‘Prostate Cancer- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Prostate Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Prostate Cancer Understanding
Prostate cancer a type of malignancy that occurs in the prostate gland. The prostate is a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm. It is located next to the bladder and can be examined by getting a digital rectal exam. Prostate cancer is one of the most common types of cancer found in men. This cancer usually grows slowly and is confined to the prostate gland initially, where it may not cause serious harm. According to the Cancer Treatment Centers of America (CTCA), more than 99% of prostate cancers are adenocarcinomas, which develop in the gland cells. It is common in men of 50–64 years and over age 65; however, it can occur in men younger than 50 years. Symptoms of adenocarcinoma of the prostate include blood in the semen, frequent urge to urinate, and painful urination and ejaculation. The symptoms of prostate cancer do not usually appear until the prostate is large enough to affect the tube that carries urine from the bladder out of the penis.

Many patients undergo regular prostate cancer screening before symptoms appear. Screening may involve one or more of the following tests: prostate-specific antigen (PSA), digital rectal exam (DRE), prostate ultrasound, prostate MRI, prostate Mp-MRI. Screening is a type of testing to find cancer in people before they have symptoms. It is not clear, however, if the benefits of prostate cancer screening outweigh the risks for most men. Still, after discussing the pros and cons of screening with their doctors, some men might reasonably choose to be screened. If the result of one of these tests is abnormal, patients will probably need a prostate biopsy to know for sure the occurrence of cancer. Clinical Stage and treatment pattern are key factors in Prostate Cancer.

“In clinical-stage-wise cases of prostate cancer, most of the cases were of the localized stage, which accounted for approximately 60% of the total diagnosed prevalent cases in 2017. On the other hand, metastatic cases accounted for only 7% of the total diagnosed prevalent cases.”

Patients who have never received, i.e., are sensitive to ADT known as hormone-sensitive prostate cancer (HSPC) or castrate-sensitive prostate cancer (CSPC). Further down the line, many prostate cancers patients ultimately fail to respond to ADT and are termed castrate-resistant prostate cancer (CRPC).

“It was accessed that around 78% of biochemical recurrence/ progressive cases are non-metastatic castrate sensitive prostate cancer (nmCSPC/ nmHSPC).”

Epidemiology Perspective by DelveInsight
The Prostate Cancer epidemiology division provides the insights about historical and current patient pool and forecasted trend for each seven major countries. The Prostate Cancer epidemiology data are studied through Prostate Cancer possible division to give a better understanding of the Disease scenario in the 7MM.

The disease epidemiology covered in the report provides historical as well as forecasted Prostate Cancerepidemiology [segmented as Total Prevalent Cases of Prostate Cancer, Total Diagnosed Cases of Prostate Cancer, Age-specific Cases of Prostate Cancer, Total Diagnosed cases of Prostate Cancer patients by Clinical Stages, Total Non-metastatic and Metastatic Cases of CSPC/HSPC and CRPC, Total Treated cases of Non-metastatic CSPC/HSPC and CRPC, Total Treated Cases of mHSPC/CSPC] scenario of Prostate Cancer in the 7MM covering the United States, EU5 countries (Germany, France, Italy , Spain, and the United Kingdom), and Japan from 2017 to 2030.

Prostate Cancer Detailed Epidemiology Segmentation
• The total prevalent cases of Prostate Cancer in the 7MM were observed to be 6,742,385 cases in 2017, and are expected to increase during the study period.
• Estimates show the highest diagnosed population of Prostate Cancer is in the United States. in EU-5 countries, the highest number of diagnosed prevalent cases of prostate cancer was found in Germany with 360,916 cases in 2017, followed by France and Italy.
• Our estimation suggested that the total treated patient pool of mCSPC/HSPC was 75,600 in 2017, will likely increase throughout the study period, besides nearly 73,452 cases of mCRPC treated in first-line.
• According to the DelveInsight, in 2017, total treated pool nmCRPC progressed from first-line to the second-line was found to be 160,287. On the other hand, the total treated patient pool of nmCSPC/HSPC was 668,577 cases in the 7MM (2017).

Scope of the Report
• The Prostate Cancer report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• The Prostate Cancer Report and Model provide an overview of the risk factors and global trends of Prostate Cancer in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan).
• The report provides insight about the historical and forecasted patient pool of Prostate Cancer in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Prostate Cancer.
• The report provides the segmentation of the Prostate Cancer epidemiology by total prevalent cases of Prostate Cancer in the 7MM.
• The report provides the segmentation of the Prostate Cancer epidemiology by total diagnosed prevalent cases of Prostate Cancer in the 7MM.
• The report provides the segmentation of the Prostate Cancer epidemiology by total diagnosed cases of Prostate Cancer patients by clinical stages in the 7MM.
• The report provides the segmentation of the Prostate Cancer epidemiology by Age-specific Cases in the 7MM.
• The report provides the segmentation of the Prostate Cancer epidemiology by Non-metastatic and Metastatic Cases of CSPC/HSPC and CRPC in the 7MM.
• The report provides the segmentation of the Prostate Cancer epidemiology by Treated cases of Non-metastatic CSPC/HSPC and CRPC in the 7MM.
• The report provides the segmentation of the Prostate Cancer epidemiology by Treated Cases of mHSPC/CSPC in the 7MM.

Report Highlights
• 11-Year Forecast of Prostate Cancer epidemiology
• 7MM Coverage
• Total Prevalent Cases of Prostate Cancer
• Total Diagnosed Cases of Prostate Cancer
• Age-specific Cases of Prostate Cancer
• Total Diagnosed cases of Prostate Cancer patients by Clinical Stages
• Total Non-metastatic and Metastatic Cases of CSPC/HSPC and CRPC
• Total Treated cases of Non-metastatic CSPC/HSPC and CRPC
• Total Treated Cases of mHSPC/CSPC

KOL-Views
We interview, KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over Prostate Cancer scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Prostate Cancer?
• What are the key findings pertaining to the Prostate Cancer epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017–2030)?
• What would be the total number of patients of Prostate Cancer across the 7MM during the study period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2017–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of Prostate Cancer?
Reasons to buy
The Prostate Cancer Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Prostate Cancer market
• Quantify patient populations in the global Prostate Cancer market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Prostate Cancer therapeutics in each of the markets covered
• Understand the magnitude of Prostate Cancer population by its severity
• The Prostate Cancer epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The Prostate Cancer Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Perio
d: 2017–2030
Prostate cancer is most frequently diagnosed among men aged 65–74 years, median age at diagnosis is 66 years. According to DelveInsight’s analysts the total number of age-specific cases in the United States for the age-group 65–74 years, was found to be 500,926, in 2017


1. Key Insights
2. Executive Summary of Prostate Cancer
3. Prostate Cancer: Disease Background and Overview
3.1. Introduction
3.1.1. Signs and Symptoms of Prostate Cancer
3.1.2. Risk Factors and Causes of Prostate Cancer
3.1.3. Pathophysiology of Prostate Cancer
3.1.4. Prostate Neoplasia
3.1.5. Genetics of Prostate Cancer
4. Diagnosis of Prostate Cancer
4.1. Screening Tests for Prostate Cancer
4.2. Tests to Diagnose Prostate Cancer
4.3. Stages and Grades of Prostate Cancer
5. Epidemiology and Patient Population
5.1. Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Total Prevalent Cases of Prostate Cancer in the 7MM
5.3.2. Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the 7MM
5.3.3. Total Non-metastatic and Metastatic Cases of CSPC/HSPC and CRPC in the 7MM
5.3.4. Total Treated cases of Non-metastatic CSPC/HSPC and CRPC Patients in the 7MM
5.3.5. Total Treated Cases of Metastatic CSPC/HSPC and CRPC Patients in the 7MM
5.4. The United States Epidemiology
5.4.1. Total Diagnosed Cases of Prostate Cancer in the United States
5.4.2. Age-specific Cases of Prostate Cancer in the United States
5.4.3. Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the United States
5.4.4. Total Non-metastatic and Metastatic Cases of CSPC/HSPC and CRPC in the United States
5.4.5. Total Treated cases of Non-metastatic CSPC/HSPC and CRPC Patients in the United States
5.4.6. Total Treated Cases of Metastatic CSPC/HSPC and CRPC Patients in the United States
6. EU-5 Country-wise Epidemiology
6.1. Germany
6.1.1. Total Diagnosed Prevalent cases of Prostate Cancer in Germany
6.1.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Germany
6.1.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Germany
6.1.4. Total Non-metastatic and Metastatic Cases of CSPC/HSPC and CRPC in Germany
6.1.5. Total Treated cases of Non-metastatic CSPC/HSPC and CRPC Patients in Germany
6.1.6. Total Treated Cases of Metastatic CSPC/HSPC and CRPC Patients in Germany
6.2. France
6.2.1. Total Diagnosed Prevalent cases of Prostate Cancer in France
6.2.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in France
6.2.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in France
6.2.4. Total Non-metastatic and Metastatic Cases of CSPC/HSPC and CRPC in France
6.2.5. Total Treated cases of Non-metastatic CSPC/HSPC and CRPC Patients in France
6.2.6. Total Treated Cases of Metastatic CSPC/HSPC and CRPC Patients in France
6.3. Italy
6.3.1. Total Diagnosed Prevalent cases of Prostate Cancer in Italy
6.3.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Italy
6.3.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Italy
6.3.4. Total Non-metastatic and Metastatic Cases of CSPC/HSPC and CRPC in Italy
6.3.5. Total Treated cases of Non-metastatic CSPC/HSPC and CRPC Patients in Italy
6.3.6. Total Treated Cases of Metastatic CSPC/HSPC and CRPC Patients in Italy
6.4. Spain
6.4.1. Total Diagnosed Prevalent cases of Prostate Cancer in Spain
6.4.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Spain
6.4.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Spain
6.4.4. Total Non-metastatic and Metastatic Cases of CSPC/HSPC and CRPC in Spain
6.4.5. Total Treated cases of Non-metastatic CSPC/HSPC and CRPC Patients in Spain
6.4.6. Total Treated Cases of Metastatic CSPC/HSPC and CRPC Patients in Spain
6.5. United Kingdom
6.5.1. Total Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom
6.5.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom
6.5.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in the United Kingdom
6.5.4. Total Non-metastatic and Metastatic Cases of CSPC/HSPC and CRPC in the United Kingdom
6.5.5. Total Treated cases of Non-metastatic CSPC/HSPC and CRPC Patients in the United Kingdom
6.5.6. Total Treated Cases of Metastatic CSPC/HSPC and CRPC Patients in the United Kingdom
6.6. Japan
6.6.1. Total Diagnosed Prevalent cases of Prostate Cancer in Japan
6.6.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Japan
6.6.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Japan
6.6.4. Total Non-metastatic and Metastatic Cases of CSPC/HSPC and CRPC in Japan
6.6.5. Total Treated cases of Non-metastatic CSPC/HSPC and CRPC Patients in Japan
6.6.6. Total Treated Cases of Metastatic CSPC/HSPC and CRPC Patients in Japan
7. Appendix
7.1. Bibliography
7.2. Report Methodology
8. DelveInsight Capabilities
9. Disclaimer
10. About DelveInsight
Table 1 Summary of Prostate Cancer Epidemiology (2017–2030)
Table 2 Genetic Changes Associated with Prostate Cancer Tumorigenesis
Table 3 Total Prevalent Cases of Prostate Cancer in the 7MM (2017–2030)
Table 4 Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the 7MM (2017–203
Table 5 Total Non-metastatic Cases of CSPC/HSPC and CRPC in the 7MM (2017–2030)
Table 6 Total Metastatic Cases of CSPC/HSPC and CRPC in the 7MM (2017–2030)
Table 7 Total Treated Cases of nmHSPC/CSPC in the 7MM (2017–2030)
Table 8 Total Treated Cases of nmCRPC by Line of Therapies in the 7MM (2017–2030)
Table 9 Total Treated Cases of mHSPC/CSPC in the 7MM (2017–2030)
Table 10 Total Treated Cases of mCRPC by Line of Therapies in the 7MM (2017–2030)
Table 11 Total Diagnosed Cases of Prostate Cancer in the United States (2017–2030)
Table 12 Age-specific Cases of Prostate Cancer in the United States (2017–2030)
Table 13 Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the United States
Table 14 Total Non-metastatic Cases of CSPC/HSPC and CRPC in the United States (2017–2030
Table 15 Total Metastatic Cases of CSPC/HSPC and CRPC in the United States (2017–2030)
Table 16 Total Treated Cases of nmHSPC/CSPC in the United States (2017–2030)
Table 17 Total Treated Cases of nmCRPC by Line of Therapies in the United States (2017–20
Table 18 Total Treated Cases of mHSPC/CSPC in the United States (2017–2030)
Table 19 Total Treated Cases of mCRPC by Line of Therapies in the United States (2017–203
Table 20 Total Diagnosed Prevalent cases of Prostate Cancer in Germany (2017–2030)
Table 21 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Germany (2017–2030)
Table 22 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Germany
Table 23 Total Non-metastatic Cases of CSPC/HSPC and CRPC in Germany (2017–2030)
Table 24 Total Metastatic Cases of CSPC/HSPC and CRPC in Germany (2017–2030)
Table 25 Total Treated Cases of nmHSPC/CSPC in Germany (2017–2030)
Table 26 Total Treated Cases of nmCRPC by Line of Therapies in Germany (2017–2030)
Table 27 Total Treated Cases of mHSPC/CSPC in Germany (2017–2030)
Table 28 Total Treated Cases of mCRPC by Line of Therapies in Germany (2017–2030)
Table 29 Total Diagnosed Prevalent cases of Prostate Cancer in France (2017–2030)
Table 30 Age-specific Diagnosed Prevalent cases of Prostate Cancer in France (2017–2030)
Table 31 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in France
Table 32 Total Non-metastatic Cases of CSPC/HSPC and CRPC in France (2017–2030)
Table 33 Total Metastatic Cases of CSPC/HSPC and CRPC in France (2017–2030)
Table 34 Total Treated Cases of nmHSPC/CSPC in France (2017–2030)
Table 35 Total Treated Cases of nmCRPC by Line of Therapies in France (2017–2030)
Table 36 Total Treated Cases of mHSPC/CSPC in France (2017–2030)
Table 37 Total Treated Cases of mCRPC by Line of Therapies in France (2017–2030)
Table 38 Total Diagnosed Prevalent cases of Prostate Cancer in Italy (2017–2030)
Table 39 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Italy (2017–2030)
Table 40 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Italy (
Table 41 Total Non-metastatic Cases of CSPC/HSPC and CRPC in Italy (2017–2030)
Table 42 Total Metastatic Cases of CSPC/HSPC and CRPC in Italy (2017–2030)
Table 43 Total Treated Cases of nmHSPC/CSPC in Italy (2017–2030)
Table 44 Total Treated Cases of nmCRPC by Line of Therapies in Italy (2017–2030)
Table 45 Total Treated Cases of mHSPC/CSPC in Italy (2017–2030)
Table 46 Total Treated Cases of mCRPC by Line of Therapies in Italy (2017–2030)
Table 47 Total Diagnosed Prevalent cases of Prostate Cancer in Spain (2017–2030)
Table 48 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Spain s(2017–2030)
Table 49 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Spain (
Table 50 Total Non-metastatic Cases of CSPC/HSPC and CRPC in Spain (2017–2030)
Table 51 Total Metastatic Cases of CSPC/HSPC and CRPC in Spain (2017–2030)
Table 52 Total Treated Cases of nmHSPC/CSPC in Spain (2017–2030)
Table 53 Total Treated Cases of nmCRPC by Line of Therapies in Spain (2017–2030)
Table 54 Total Treated Cases of mHSPC/CSPC in Spain (2017–2030)
Table 55 Total Treated Cases of mCRPC by Line of Therapies in Spain (2017–2030)
Table 56 Total Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom (2017–20
Table 57 Age-specific Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom
Table 58 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in the Uni
Table 59 Total Non-metastatic Cases of CSPC/HSPC and CRPC in the United Kingdom (2017–203
Table 60 Total Metastatic Cases of CSPC/HSPC and CRPC in the United Kingdom (2017–2030)
Table 61 Total Treated Cases of nmHSPC/CSPC in the United Kingdom (2017–2030)
Table 62 Total Treated Cases of nmCRPC by Line of Therapies in the United Kingdom (2017–2
Table 63 Total Treated Cases of mHSPC/CSPC in the United Kingdom (2017–2030)
Table 64 Total Treated Cases of mCRPC by Line of Therapies in the United Kingdom (2017–20
Table 65 Total Diagnosed Prevalent cases of Prostate Cancer in Japan (2017–2030)
Table 66 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Japan (2017–2030)
Table 67 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Japan (
Table 68 Total Non-metastatic Cases of CSPC/HSPC and CRPC in Japan (2017–2030)
Table 69 Total Metastatic Cases of CSPC/HSPC and CRPC in Japan (2017–2030)
Table 70 Total Treated Cases of nmHSPC/CSPC in Japan (2017–2030)
Table 71 Total Treated Cases of nmCRPC by Line of Therapies in Japan (2017–2030)
Table 72 Total Treated Cases of mHSPC/CSPC in Japan (2017–2030)
Table 73 Total Treated Cases of mCRPC by Line of Therapies in Japan (2017–2030)
Figure 1 Prostate Cancer
Figure 2 Sign and Symptoms of Prostate Cancer
Figure 3 Risks Factors of Prostate Cancer
Figure 4 Pathophysiology of Prostate Cancer
Figure 5 Progression of Prostate Cancer and the Development of mCRPC
Figure 6 Diagnosis of Prostate Cancer
Figure 7 Gleason Score of Prostate Cancer
Figure 8 Global Heat Map of Prostate Cancer
Figure 9 Total Prevalent Cases of Prostate Cancer in the 7MM (2017–2030)
Figure 10 Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the 7MM (2017–2030)
Figure 11 Total Non-metastatic Cases of CSPC/HSPC and CRPC in the 7MM (2017–2030)
Figure 12 Total Metastatic Cases of CSPC/HSPC and CRPC in the 7MM (2017–2030)
Figure 13 Total Treated Cases of nmHSPC/CSPC in the 7MM (2017–2030)
Figure 14 Total Treated Cases of nmCRPC by Line of Therapies in the 7MM (2017–2030)
Figure 15 Total Treated Cases of mHSPC/CSPC in the 7MM (2017–2030)
Figure 16 Total Treated Cases of mCRPC by Line of Therapies in the 7MM (2017–2030)
Figure 17 Total Diagnosed Cases of Prostate Cancer in the United States (2017–2030)
Figure 18 Age-specific Cases of Prostate Cancer in the United States (2017–2030)
Figure 19 Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the United States (2017–2030)
Figure 20 Total Non-metastatic Cases of CSPC/HSPC and CRPC in the United States (2017–2030)
Figure 21 Total Metastatic Cases of CSPC/HSPC and CRPC in the United States (2017–2030)
Figure 22 Total Treated Cases of nmHSPC/CSPC in the United States (2017–2030)
Figure 23 Total Treated Cases of nmCRPC by Line of Therapies in the United States (2017–2030)
Figure 24 Total Treated Cases of mHSPC/CSPC in the United States (2017–2030)
Figure 25 Total Treated Cases of mCRPC by Line of Therapies in the United States (2017–2030)
Figure 26 Total Diagnosed Prevalent cases of Prostate Cancer in Germany (2017–2030)
Figure 27 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Germany (2017–2030)
Figure 28 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Germany (2017–2030)
Figure 29 Total Non-metastatic Cases of CSPC/HSPC and CRPC in Germany (2017–2030)
Figure 30 Total Metastatic Cases of CSPC/HSPC and CRPC in Germany 2017–2030)
Figure 31 Total Treated Cases of nmHSPC/CSPC in Germany 2017–2030
Figure 32 Total Treated Cases of nmCRPC by Line of Therapies in Germany (2017–2030)
Figure 33 Total Treated Cases of mHSPC/CSPC in Germany (2017–2030)
Figure 34 Total Treated Cases of mCRPC by Line of Therapies in Germany (2017–2030)
Figure 35 Total Diagnosed Prevalent cases of Prostate Cancer in France (2017–2030)
Figure 36 Age-specific Diagnosed Prevalent cases of Prostate Cancer in France (2017–2030)
Figure 37 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in France (2017–2030)
Figure 38 Total Non-metastatic Cases of CSPC/HSPC and CRPC in France (2017–2030)
Figure 39 Total Metastatic Cases of CSPC/HSPC and CRPC in France2017–2030)
Figure 40 Total Treated Cases of nmHSPC/CSPC in France (2017–2030)
Figure 41 Total Treated Cases of nmCRPC by Line of Therapies in France (2017–2030)
Figure 42 Total Treated Cases of mHSPC/CSPC in France (2017–2030)
Figure 43 Total Treated Cases of mCRPC by Line of Therapies in France (2017–2030)
Figure 44 Total Diagnosed Prevalent cases of Prostate Cancer in Italy (2017–2030)
Figure 45 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Italy (2017–2030)
Figure 46 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Italy (2017–2030)
Figure 47 Total Non-metastatic Cases of CSPC/HSPC and CRPC in Italy (2017–2030)
Figure 48 Total Metastatic Cases of CSPC/HSPC and CRPC in Italy 2017–2030)
Figure 49 Total Treated Cases of nmHSPC/CSPC in Italy (2017–2030)
Figure 50 Total Treated Cases of nmCRPC by Line of Therapies in Italy (2017–2030)
Figure 51 Total Treated Cases of mHSPC/CSPC in Italy (2017–2030)
Figure 52 Total Treated Cases of mCRPC by Line of Therapies in Italy (2017–2030)
Figure 53 Total Diagnosed Prevalent cases of Prostate Cancer in Spain (2017–2030)
Figure 54 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Spain (2017–2030)
Figure 55 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Spain (2017–2030)
Figure 56 Total Non-metastatic Cases of CSPC/HSPC and CRPC in Spain (2017–2030)
Figure 57 Total Metastatic Cases of CSPC/HSPC and CRPC in Spain (2017–2030)
Figure 58 Total Treated Cases of nmHSPC/CSPC in Spain (2017–2030)
Figure 59 Total Treated Cases of nmCRPC by Line of Therapies in Spain (2017–2030)
Figure 60 Total Treated Cases of mHSPC/CSPC in Spain (2017–2030)
Figure 61 Total Treated Cases of mCRPC by Line of Therapies in Spain (2017–2030)
Figure 62 Total Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom (2017–2030)
Figure 63 Age-specific Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom (2017–2030)
Figure 64 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in the United Kingdom (2017–2030)
Figure 65 Total Non-metastatic Cases of CSPC/HSPC and CRPC in the United Kingdom (2017–2030)
Figure 66 Total Metastatic Cases of CSPC/HSPC and CRPC in the United Kingdom (2017–2030)
Figure 67 Total Treated Cases of nmHSPC/CSPC in the United Kingdom (2017–2030)
Figure 68 Total Treated Cases of nmCRPC by Line of Therapies in the United Kingdom (2017–2030)
Figure 69 Total Treated Cases of mHSPC/CSPC in the United Kingdom (2017–2030)
Figure 70 Total Treated Cases of mCRPC by Line of Therapies in the United Kingdom (2017–2030)
Figure 71 Total Diagnosed Prevalent cases of Prostate Cancer in Japan (2017–2030)
Figure 72 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Japan (2017–2030)
Figure 73 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Japan (2017–2030)
Figure 74 Total Non-metastatic Cases of CSPC/HSPC and CRPC in Japan (2017–2030)
Figure 75 Total Metastatic Cases of CSPC/HSPC and CRPC in Japan (2017–2030)
Figure 76 Total Treated Cases of nmHSPC/CSPC in Japan (2017–2030)
Figure 77 Total Treated Cases of nmCRPC by Line of Therapies in Japan (2017–2030)
Figure 78 Total Treated Cases of mHSPC/CSPC in Japan (2017–2030)
Figure 79 Total Treated Cases of mCRPC by Line of Therapies in Japan (2017–2030)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook